AL/OE-TR-1996-0089



UNITED STATES AIR FORCE ARMSTRONG LABORATORY

Inhalation Uptake and Metabolism of lodohalogenated Compounds, CF_3I , $C_6F_{13}I$, and C_3F_7I

J.R. Creech R.K. Black B.L. Garrity R.J. Williams J.N. McDougal G.W. Jepson

TOXICOLOGY DIVISION WRIGHT-PATTERSON AFB, OH 45433-7400

> R. Abbas L. Dong

GEO-CENTERS, INC. 7 WELLS AVENUE NEWTON CENTRE, MA 02159

A. Vinegar

MANTECH ENVIRONMENTAL TECHNOLOGY, INC. P.O. BOX 31009 DAYTON, OH 45437

19970512 082

April 1995

Approved for public release;

distribution is unlimited.

Occupational and Environmental Health Directorate Toxicology Divison 2856 G. St. Wright-Patterson AFB OH 45433-7400

NOTICES

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Armstrong Laboratory. Additional copies may be purchased from:

NATIONAL TECHNICAL INFORMATION SERVICE 5285 PORT ROYAL ROAD SPRINGFIELD, VIRGINIA 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

DEFENSE TECHNICAL INFORMATION CENTER 8725 JOHN J. KINGMAN RD STE 0944 FT BELVOIR VA 22060-6218

DISCLAIMER

This Technical Report is published as received and has not been edited by the Technical Editing Staff of the Armstrong Laboratory.

TECHNICAL REVIEW AND APPROVAL AL/OE-TR-1995-0089

The animals used in this study were handled in accordance with the principles stated in the *Guide* for the Care and Use of Laboratory Animals prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, National Academy Press, 1996, and the Animal Welfare Act of 1966, as amended.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE COMMANDER

Deny A. Children

TERRY A. CHILDRESS, Lt Col, USAF, BSC Director, Toxicology Division Armstrong Laboratory

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503					
1. AGENCY USE ONLY (Leave Blank) 2. REPORT DATE 3. REPORT TYPE AND DATES April 1995 Interim - June 1993 - N			TYPE AND DATES COV - June 1993 - Mar	vered 	
 4. TITLE AND SUBTITLE Inhalation Uptake and Me CF3I, C6F13I, and C3F7I 6. AUTHOR(S) J.R. Creech, R.K. Black, J.N McDougal, A. Vineg 7. PERFORMING ORGANIZATION ManTech Environmental P.O. Box 31009 Dayton, OH 45437 	 FUNDING NUMBER Contract F33 PE 622 PR 775 TA 775 WU 775 8. PERFORMING OF REPORT NUMBER 	ERS 615-90-C-0532 02F 7 7 7A1 7A102 RGANIZATION R			
 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Armstrong Laboratory, Occupational and Environmental Health Directorate Toxicology Division, Human Systems Center Air Force Materiel Command Wright-Patterson AFB OH 45433-7400 10. SPONSORING/MONITORING AGENCY REPORT NUMBER AL/OE-TR-1995-0089 11. SUPPLEMENTARY NOTES 					
12a. DISTRIBUTION/AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for public release; distribution is unlimited. 12b. DISTRIBUTION CODE					
 The purpose of this study was to measure the tissue to air partition coefficients and to describe the uptake and distribution kinetics of iodohalogenated compounds iodotrifluoromethane (CF₃I), perfluorohexyl iodide (C₆F₁₃I) and 1-iodoheptafluoropropane (C₃F₇I) via closed chamber recirculating gas uptake methods. Inhalation pharmacokinetics for all chemicals were determined experimentally in Fischer-344 (F-344) male rats. A physiologically based pharmacokinetic (PBPK) model was used to describe mathematically the disposition and metabolism of the chemicals employing chemical-specific parameters and apparent whole-body metabolic constants calculated from these experiments. 					
14. SUBJECT TERMS		· · · · · · · · · · · · · · · · · · ·	15. NUMB	ER OF PAGES	
Partition coefficients Rats	Iodohalogenated compounds PBPK	Gas uptake Metabolism	16. PRICE	CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFIC OF ABSTRACT UNCLASSIFIED	CATION 20. LIMITA	ATION OF ABSTRACT	

NSN 7540-01-280-5500

1

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

.

THIS PAGE INTENTIONALLY LEFT BLANK

PREFACE

The research reported herein was conducted by the Toxic Hazards Research Unit, Man Tech Environmental Technology Inc., and serves as a technical report for the determination of the gas uptake kinetic of - iodotrifluoromethane (CF₃I), perfluorohexyl iodide (C₆F₁₃I), and 1-Iodoheptafluoropropane (C₃F₇I). The research described in this report began in June 1993 and was completed in Mar 1995.

DTIC QUALITY INSPECTED 3

TABLE OF CONTENTS

SECTION

PAGE

	Preface	iii
	List of Figures	V
	List of Tables	vi
	Abbreviations	vii
1	INTRODUCTION	
2	MATERIALS AND METHODS	
	Test Materials	2
	Animals	2
	Determination of Partition Coefficient	
	Gas Uptake and Metabolic Constants	
	Model Development	
	PBPK Model Construction	
3	RESULTS	
4	DISCUSSION	
5	CONCLUSION	
6	REFERENCES	14

LIST OF FIGURES

FIGURE		
1	Illustration of Closed Chamber Recirculating Gas Uptake System	5
2	A Scheme of PBPK Model for Computer Simulations of Iodohalogenated Compounds Disposition and Metabolism in Rats	7
3	$C_6F_{13}I$ Gas Uptake - Comparision of First-Order Metabolism and No Metabolism with the Same Loss Rates	. 10
4	C ₃ F ₇ I Gas Uptake - Comparision of First-Order Metabolism and No Metabolism with the Same Loss Rate	11

LIST OF TABLES

TABLE		PAGE
1	Kinetic Constants and Physiological Parameters Used in PBPK Modeling in Rats	6
2	Partition Coefficients for Iodohalogenated Compounds	8
3	Summary of Metabolic Constants and Chamber Loss Rates Used in Simulating Uptake of Iodohalogenated Compounds	9

TARTE

ABBREVIATIONS

°C	Degrees Celsius
F-344	Fischer 344 (rats)
FID	Flame ionization detector
g	Gram
GC	Gas chromatograph(y)
h	Hour
hrs	Hours
t	Time
L	Liter
m	Meter
min	Minute
mL	Milliliter
ppm	Parts per million
BW	Body weight
mm	Millimeter
PBPK	Physiological Based Pharmacokinetic
CF ₃ I	Iodotrifluoromethane
$C_{6}F_{13}I$	Perfluorohexyl Iodide
C ₃ F ₇ I	1-Iodoheptafluoropropane

†.

THIS PAGE INTENTIONALLY LEFT BLANK

ς.

SECTION 1 INTRODUCTION

The purpose of this study was to measure the tissue to air partition coefficients and to describe the uptake and distribution kinetics of iodohalogenated compounds iodotrifluoromethane (CF₃I), perfluorohexyl iodide (C₆F₁₃I), and 1-iodoheptafluoropropane (C₃F₇I) via closed chamber recirculating gas uptake methods.

Inhalation pharmacokinetics for all chemicals were determined experimentally in Fischer-344 (F-344) male rats. A physiologically based pharmacokinetic (PBPK) model was used to describe mathematically the disposition and metabolism of the chemicals employing chemicalspecific parameters and apparent whole-body metabolic constants calculated from these experiments

SECTION 2 METHODS/MATERIALS

Test Materials

Iodotrifluoromethane (CF₃I):

PCR Inc. (Gainesville, FL)
Trifluoromethyl Iodide
2314-97-8
195.9 g
CF ₃ I
-22.5

Perfluorohexyl Iodide (C_6F_{13} I):

ManufacturerAldrich Chemical Co., Inc. (Milwaukee, WI)Trade NamePerfluorohexyl IodideCAS #355-43-1Mol. Weight445.95 gEmpirical Formula $CF_3-CF_2-CF_2-CF_2-CF_2I$ Boiling Point (°C)117

1-Iodoheptafluoropropane (C₃F₇I):

ManufacturerFlura Corporation, Newport, TNCAS #754-34-7Mol. Weight295.93gEmpirical FormulaCF3-CF2-CF2IBoiling Point (°C)40

Animals

Male Fischer 344 (F-344) (200 to 350 g) rats (*Rattus norvegicus*) were obtained from Charles River Breeding Laboratories (Kingston, NY). Animals received Purina Formulab #5008 and softened water *ad libitum*. They were housed in plastic cages (2-3/cage) with hardwood chip bedding prior to exposure and were maintained on a 12-hr light/ 12-hr dark light cycle at constant temperature ($22 + /-1^{\circ}C$) and humidity (40-60%). Cages were changed twice per week. Animals were marked for identification with a tail tattoo.

The animals used in this study were handled in accordance with the principles stated in the *Guide for the Care and Use of Laboratory Animals*, prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animals Resources, National Research Council, DHHS. National Institute of Health Publication #86-23, 1985, and the Animal Welfare Act of 1966, as amended.

Partition Coefficients

Partition coefficients were determined by using a modified version of the vialequilibration technique described by Gargas *et al.* (1989). Whole tissue was harvested and minced into a tissue slurry versus prepared as a tissue homogenate in saline. Rats used to determine partition coefficients were sacrificed with CO₂. Blood was collected from the posterior vena cava using a heparinized syringe. Liver, muscle (quadriceps), and fat (epididymal and perirenal) were also removed for analysis. Blood samples (1.0 mL for all chemicals) were placed in 12.4 mL glass vials and incubated/ mixed for 3 hrs at 37°C with 400 ppm of chemical (800 ppm for CF₃I) in the vial headspace. Whole tissue samples (1.0 g of liver and muscle, and 0.5 g of fat for all chemicals) were minced and incubated/mixed under the same condition as for blood, except fat was equilibrated for 5-8 hrs. Partition coefficients were also determined at 80 and 400 ppm to show that they were concentration independent.

The chemical concentrations in the headspace were analyzed using a HP19395A headspace sampler (Hewlett-Packard, Avondale, PA) connected to a HP5890A gas chromatograph (GC) (Hewlett-Packard, Palo Alto, CA) equipped with a hydrogen flame ionization detector. Column selection and GC conditions varied for each chemical. CF₃I and C₆F₁₃I a 12' x 1/8" stainless steel 10% SE-30, WHP 80/100 mesh Chromsorb column was used. A DB-17 column was used for C₃F₇I. GC conditions were set with the detector temperature at 250°C for CF₃I and C₆F₁₃I and 300°C for C₃F₇I, injector temperature at 125°C, nitrogen carrier gas flow at 30.0 mL/min, and an oven temperature held constant at 60°C for CF₃I, 80°C for C₃F₇I, and 100°C for C₆F₁₃I.

Gas Uptake and Metabolic Constants

Figure 1 illustrates the closed chamber recirculating gas uptake system with a volume of 8.0 L that was used for the estimation of the whole animal metabolic constants (V_{max} , K_m , and/or K_f). The condenser was removed for $C_6F_{13}I$ and C_3F_7I . Three F-344 rats were exposed to each study chemical using a gas uptake system similar to that described by Gargas et al. (1986). Initially, a predetermined concentration of the test chemical was introduced into the system so that the concentration in the chamber atmosphere decreases as the chemical is taken up and metabolized by the rat. Four to five exposure concentrations were performed for 6 hours for each chemical (CF₃I concentrations were 112, 648, 1228, 2727 and 5867 ppm; $C_6F_{13}I$ concentrations were 124, 540, 1043, and 4822 ppm; C_3F_7I concentrations were 245, 1108, 3012, and 5126 ppm). Sodium hydroxide (75-150 g) was used as the CO₂ absorber for CF₃I. Barium hydroxide (75 g) was used as the CO₂ absorber for C₃F₇I and C₆F₁₃I. Oxygen concentrations were maintained at (21 +/- 1%) during the exposures. The system flow was maintained at 2.1 L/min with the flow to the sample loop of the GC at 100 mL/min.

The chemical concentrations in the chamber atmosphere were monitored every 5 min for the first 30 min and every 15 min thereafter using an automated gas sampling valve connected to a HP5890A gas chromatograph. Chromatography was performed on a 25m x 0.53 mm Chrompack PoraPLOT Q (Plot Fused Silica) column for CF₃I. The GC was equipped with a hydrogen flame ionization detector with a temperature of 250°C, helium carrier flow at 12.1 mL/min with make-up flow of 14.2 mL/min, injector at 125°C, and an oven temperature held constant at 125°C for CF₃I. Chromatography was performed on a 10% SE-30, WHP 80/100 mesh Chromosorb 12' x 1/8' ss column for C₆F₁₃I and C₃F₇I. The

3

detector (FID) temperature was 250°C, injector temperature was 125°C, oven temperature was held constant at 100°C for $C_6F_{13}I$ and at 50°C for C_3F_7I , and helium carrier flow was at 30 mL/min.

Model Development -

SIMUSOLV (DOW Chemical Co., Midland, MI), a FORTRAN-based continuous simulation language with optimization capabilities was used on a VAX/VMS 8530 mainframe computer (Digital Equipment Corp., Maynard, MA). Figure 2 shows a general form of a PBPK model. The codes that made up the PBPK models are given in the Appendices. Parameters were optimized by SIMUSOLV which is using the log likelihood function as the criterion and either the generalized reduced gradient method for single parameter optimization or the Nelder-Mead search method for multiple parameters optimization to adjust the values.

Physiological constants for calculating volumes of the compartments are shown in Table 1. Tissue volume and flow constants are scaled to the actual body weight (BW) of the rats under study (fat volume was derived from Anderson et al. [1993]); other constants were according to Linstedt (Physiological Parameters Working Group, ILSI Risk Science Institute, unpublished data). Blood flows are expressed as a percentage of cardiac output that was scaled to body weight to the exponent 0.75. Alveolar ventilation is also scaled to body weight to the exponent 0.75. Cardiac output and alveolar ventilation, based on those described by Gargas et al. (1986) for resting animals, are summarized in Table 1.

Blood/air and tissue/air partition coefficients were obtained as described above. Metabolic constants were determined using the model to obtain a simultaneous fit to the closed chamber gas uptake data. The constants are scaled to BW using the allometric relationship described by Andersen et al. (1987).



5

CLOSED CHAMBER GAS UPTAKE SYSTEM

J

UPTAKE2.PPT

TABLE 1.KINETIC CONSTANTS AND PHYSIOLOGICAL PARAMETERS USED
IN PBPK MODELING IN RATS

DESCRIPTION -	[UNITS] PARAMETERS
Tissue Volumes	[Fraction of Body Weight: BW]
Liver	$V_{L}C = 0.037$
Fat	$V_{\rm F}C = 0.1*(35*BW+2.1)$
Slowly Perfused	$V_{s}C = 0.558$
Rapidly Perfused	$V_{R}C = 0.031$
Flow Rates	[L/h/kg]
Alveolar Ventilation	$Q_{\rm P}C = 14.0$
Cardiac Output	$Q_{\rm C}C = 14.0$
	[Fraction of Cardiac Output]
Liver	$Q_{L}C = 0.032$
Fat	$Q_F C = 0.058$
Slowly Perfused	$Q_{s}C = 0.255$
Rapidly Perfused	$Q_{\rm R}C = 0.472$

PBPK Model Construction

Figure 2 shows the scheme of the PBPK model, essentially as described by Ramsey and Andersen (1984). Mass transfer differential equations describing each department of the PBPK model for all chemicals are presented below.

For simple, well-stirred compartments in which neither metabolism nor other losses occurred (rapidly and slowly perfused tissues, and fat), the change in the amount of chemical (A_i) over time (t) was described as follows:

$dA_i/dt = Q_i(CA-CV_i)$

where subscript i represents "i-th" compartment; Q_i represents the blood flow through the "i-th" compartment; CA represents the arterial concentration; CV_i represents the venous concentration leaving the "i-th" compartment ($CV_i = C_i/P_i$; where C_i is a concentration in the tissues in the "i-th" compartment and P_i is the tissue/ blood partition coefficient for the "i-th" compartment. $C_i = A_i/V_i$, where V_i represents the volume of the "i-th" compartment).

For the liver compartment, a loss term (RAM) was added to he well-stirred compartment description to account for rate of metabolism (RAM = $V_{max} CV_L/(K_m + CV_L) + K_f CV_L V_L$; where V_{max} is apparent-maximal velocity rate of metabolism, CV_L is venous concentration leaving the liver, K_m is apparent Michaelis-Menten constant, K_f is the first-order rate of metabolism, and V_L is the volume of the liver):

 $dA_L / dt = Q_L (CA - CV_L) - RAM$

Units for the above variables are as follows: amounts-mg, concentrations-mg/L, flows-L/h, and rates-mg/h. The actual codes and command files used for computer simulation of the Iodohalogenated compounds are included in the appendices.



Figure 2. A Scheme of PBPK model used for the computer simulations of Halon 1301 and its proposed replacements disposition and metabolism in rats.

SECTION 3 RESULTS

Partition Coefficients -

Shown in Table 2 are the rat tissue to air partition coefficients determined for $CF_{3}I$, $C_{6}F_{13}I$, and $C_{3}F_{7}I$, which were used in the PBPK model optimization. Due to the extremely low partition coefficient for FC-218, higher amounts of rat tissue were used.

TABLE 2. PARTITION COEFFICIENTS FOR IODOHALOGENATE COMPOUNDS				
Partition Co	peffients	CF ₃ I (n = 10)	$C_{6}F_{13}I$ (n = 5)	$C_{3}F_{7}I$ (n = 5)
Blood:air	PB	1.73 ± 0.28	0.94 <u>+</u> 0.2	0.54 + 0.3
Liver:air	PLA	1.27 <u>+</u> 0.21	0.90 <u>+</u> 0.4	0.02 + 0.27
Fat:air	PFA	10.35 <u>+</u> 0.82	130.6+17.9	11.21 + 1.53
Rapidly				
perfused:air	PRA	1.27 <u>+</u> 0.21	0.90 ± 0.4	0.02 + 0.27
Slowly				
perfused:air	PSA	1.32 <u>+</u> 0.18	1.0 ± 0.2	0.50 + 0.27

Gas Uptake Studies

The inhalation uptake of CF₃I was reported in AL/OE-TR-1994-0068. The rat showed two discernible phases: a rapid equilibration phase that lasted up to 60 min followed by a slow linear uptake phase. Simulation of uptake of CF₃I required some attribution of metabolic capacity by the rats. Attribution of both saturable ($V_{maxc} = 0.375$, $K_m = 0.1$) and first order ($K_{fc} = 1.6$) metabolism and a chamber loss of 2.7% is shown compared to no metabolism with the same chamber loss rate. The upper curve with each set of data represents the no metabolism condition. Attribution of saturable ($V_{maxc} = 0.375$, $K_m = 0.1$) metabolism alone and a chamber loss of 4% is shown compared to no metabolism with a chamber loss of 2.7%. Comparing the simulations with metabolism and the simulations without metabolism, virtually overlapping each other. This indicates a lack of discrimination between first order metabolism and chamber loss for CF₃I.

The inhalation uptake of $C_6F_{13}I$ also had two phase: a two hour equilibration phase followed by a slow linear uptake phase. The two hour equilibration phase is caused by the chemcial's absorption to the barium hydroxide. Simulation of uptake of $C_6F_{13}I$ required some attribution of metabolic capacity by the rats. First order ($K_{fc} = 8.61$) metabolism with a chamber loss rates of 7.25% for the first two hours and 2.23% for the last four hours is shown compared to no metabolism with the same chamber loss rates (Figure 3). Simulation of C_3F_7I required some attribution of metabolic capacity by the rats. First order ($K_{fc} = 142.21$) metabolism with a chamber loss rate of 1.9% per hr (Figure 4).

The constants and rates used for each of the preceding simulations are summarized in Table 3.

FIGURE	CHEMICAL	V _{maxe} mg/h/kg	K _m mg/L	K _{fc} 1/h/kg	CHAMBER LOSS / h
*	CF ₁	0.375	0.1	1.6	2.7 %
	j-	0.0	10000	0.0	2.7 %
*	CF ₃ I	0.375	0.1	0.0	4.0 %
	•	0.0	10000	0.0	2.7 %
+	CF ₃ I	0.375	0.1	1.6	2.7 %
	-	0.375	0.1	0.0	4.0 %
3	$C_{6}F_{13}I$	0.0	10000	8.61	7.25 % (0-2 hrs)
		0.0	10000	8.61	2.23 % (2-6 hrs)
4	C ₃ F ₇ I	0.0	10000	142.21	1.9%
* Williams, et al. (1994)					

TABLE 3. SUMMARY OF METABOLIC CONSTANTS AND CHAMBER LOSS RATES USED IN SIMULATING UPTAKE OF IODOHALOGENATED COMPOUNDS BY RATS

9

Constant Rate 0 ._ Metabo Figure 3 0 f Determination





SECTION 4 DISCUSSION

This simulation approach for analysis of gas uptake data has been shown to distinguish between single and multiple metabolic pathways of several previously studied dihalomethanes and numerous other volatile organic compounds. Simulation of the CF_3I required some attribution of metabolism (saturable and first order) by the rats beyond losses to the system. Another indication that the chemical CF_3I was disappearing beyond that taken up by the chamber is demonstrated by the chromatograms of the chamber air. As gas uptake experiments progressed, a second peak appeared and increased in size. This could represent a metabolite resulting from the metabolism of the chemical by the rats or could represent a product resulting from spontaneous breakdown of CF_3I in the chamber. The product appeared only when live rats were in the chamber with the presence of the parent chemical. However, further experiments would be necessary to determine the identity and origin of the second chromatographic peak.

It was discovered in the loss runs that $C_6F_{13}I$ absorbs to the sodium hydroxide and the skin and fur of the rat. Barium hydroxide was used as the CO₂ absorber because it had a lower chamber loss rate. Since the chemical absorbs to the barium hydroxide and the animal, there is a two hour equilibration phase. Thus, the loss of chemical to the system is best explained using two chamber loss rates: 7.25% for the first two hours, and 2.23% for the last four hours. Simulation of $C_6F_{13}I$ required some attribution of metabolism (first order) by the rat beyond the losses to the system. The K_f was 8.61 1/h/kg. Another indication that the chemical was being metabolized was that the rats were very lethargic at the higher concentration. Thus, it is apparent that $C_6F_{13}I$ has an anesthetic effect on the rats.

 C_3F_7I also absorbed to sodium hydroxide, and barium hydroxide was used because of the lower chamber loss rate of 1.9% per hour. The simulation of C_3F_7I required some attribution of metabolism (first order) by the rat beyond the losses to the system. The K_f was 142.21 l/h/kg

SECTION 5 CONCLUSION

1. The PBPK model adequately describes the uptake of CF_3I , $C_6F_{13}I$, and C_3F_7I from the chamber atmosphere during the exposure experiments.

2. CF_3I has low solubility (partitioning) in blood and tissues and had minimal, if any, enzymatic metabolism in rats.

3. Further experimentation is needed to determine the identity of the second peak in the metabolism of CF_3I .

4. $C_6F_{13}I$ has an anesthetic effect on the rats.

SECTION 6 REFERENCES

Anderson, Y.B., J.A.Jackson, and L.S. Birnbaum. 1993. Maturational changes in dermal absorption of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in Fischer 344 rats. *Toxicol. Appl. Pharmacol.* 119:214-220.

Andersen, M.E., H.J. Clewell, M.L. Gargas, F.A. Smith, and R.H. Reitz. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. *Toxicol. Appl. Pharmacol.* 87:185-205.

Gargas, M.L., M.E. Andersen, and H.J. Clewell III. 1986. A physiologically based simulation approach for determining metabolic constants from gas uptake data. *Toxicol Appl. Pharmacol.* 86:341-352.

Gargas, M.L., R.J. Burgess, D.E. Voisard, G.H. Cason, and M.E. Andersen. 1989. Partition coefficients of low-molecular weight volatile chemicals in various liquids and tissues. *Toxicol. Appl. Pharmacol.* 98:87-99.

Ramsey, J.C. and M.E. Andersen. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. *Toxicol. Appl. Pharmacol.* 73:159-175.

Williams R.J., J.R. Creech, R.K. Black, S.K. Neurath, A. Vinegar, G.W. Jepson, and J.Z. Byczkowski, 1994. Gas Uptake Kineyics of Bromotrifluoromethane (Halon 1301) and Its Proposed Replacement Iodotrifluoromethane (CF₃I). AL/OE-TR-1994-0068.